Mankind Pharma Limited has informed the Exchange regarding Appointment of Ms M. K. Kulshrestha & Associates, Cost Accountants as Other of the company w.e.f. May 19, 2026.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma reported FY2025-26 standalone revenue of Rs 10,421 crore, up 9.6% from Rs 9,507 crore in prior year. However, standalone profit after tax dropped significantly to Rs 714 crore from Rs 1,786 crore in FY2025. The board approved reappointment of Whole-Time Director Satish Kumar Sharma for 5 years from September 2026, appointment of M.K. Kulshrestha & Associates as Cost Auditors for FY2026-27, and additional investment of up to Rs 500 crore in wholly-owned subsidiary Mankind Medicare Private Limited. Executive Directors (Chairman, Vice Chairman & MD, CEO) voluntarily forwent their commission for FY2025-26 to strengthen cash position for business expansion. The CIO also resigned effective May 31, 2026. Joint statutory auditors issued unmodified opinion; however, comparative prior year figures were restated for BSV acquisition and auditors drew emphasis on pending income tax proceedings.
Sharp PAT decline despite revenue growth is a concern, though the company maintains healthy margins (29% operating, 20% net) and low leverage (debt-equity 0.34). Executive commission waiver and additional subsidiary investment signal focus on cash preservation and expansion. Restatement of prior year results may affect historical comparisons.